Home › Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma clinical trials recruiting in the U.S.
178 studies for Head and Neck Squamous Cell Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- Nashville, TN39 studies
- New York City, NY39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Philadelphia, PA26 studies
- Chicago, IL26 studies
- Atlanta, GA24 studies
- Pittsburgh, PA22 studies
- New Haven, CT22 studies
- San Antonio, TX22 studies
- Dallas, TX20 studies
- Queens, NY20 studies
- Columbus, OH20 studies
- Portland, OR19 studies
- Cleveland, OH18 studies
- Durham, NC17 studies
- Orlando, FL16 studies
- Baldwin Park, CA16 studies
- Detroit, MI15 studies
- Baltimore, MD15 studies
- Tampa, FL15 studies
- Edison, NJ15 studies
- Grand Rapids, MI15 studies
- Cincinnati, OH14 studies
- Miami, FL14 studies
- San Diego, CA14 studies
- Charleston, SC14 studies
- Santa Monica, CA13 studies
- Milwaukee, WI13 studies
- Omaha, NE13 studies
- Oklahoma City, OK13 studies
- Rochester, MN12 studies
- Jacksonville, FL12 studies
- Richmond, VA12 studies
- Cedar Rapids, IA12 studies
- Ann Arbor, MI12 studies
- West Valley City, UT11 studies
By state
- Alabama7 studies
- Arizona18 studies
- Arkansas11 studies
- California72 studies
- Colorado23 studies
- Connecticut24 studies
- Delaware3 studies
- District of Columbia9 studies
- Florida53 studies
- Georgia26 studies
- Idaho4 studies
- Illinois30 studies
- Indiana13 studies
- Iowa14 studies
- Kansas9 studies
- Kentucky16 studies
- Louisiana6 studies
- Maryland18 studies
- Massachusetts42 studies
- Michigan36 studies
- Minnesota23 studies
- Missouri29 studies
- Montana5 studies
- Nebraska15 studies
- Nevada4 studies
- New Hampshire3 studies
- New Jersey26 studies
- New Mexico3 studies
- New York54 studies
- North Carolina27 studies
- North Dakota6 studies
- Ohio46 studies
- Oklahoma14 studies
- Oregon19 studies
- Pennsylvania41 studies
- Rhode Island7 studies
- South Carolina21 studies
- South Dakota9 studies
- Tennessee43 studies
- Texas69 studies
- Utah21 studies
- Vermont3 studies
- Virginia42 studies
- Washington18 studies
- Wisconsin15 studies
Recently updated studies
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06992427FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06589804A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07744126Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT04892173Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06980038A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06385080A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06736379From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.